Cover Story
HBA Woman of the Year
Patrick Clinton
Editor-in-Chief
At the helm of a billion-dollar communcations firm, Lynn O'Connor Vos wants to improve the reputation of pharma—and its marketers—for the sake of tomorrow's business leaders.
Deal Making
Keys to Success
Michael Curran-Hays and Martin Wing
Kepner-Tregoe
The playing field has leveled when it comes to pharma and biotech companies teaming up to develop or market products, making joint efforts an increasingly popular strategy.
Pricing
Risky Business
Anthony Farino and Timothy Nugent
PricewaterhouseCoopers
John T. Bentivoglio and John Shakow
King & Spalding
Every quarter, pharma manufacturers are faced with the high-stakes—and confusing—process of price reporting.
Patents
Patent Attack
Gregory Glass
Gregory Glass Associates
A rise in the number of challenges by generic manufacturers to brand name drug patents is complicating the way pharma manages its products.
Media
Pharma in the News
Stephen J. Porth and George P. Sillup
St. Joseph's University
Maybe the industry isn't paranoid after all. When it comes to ethical issues, pharma generates a lot of negative ink.
Stem Cells
Unleashing the Promise
Nicole Gray
Contributing Writer
Amid political and ethical contentions over stem cell research, several companies are moving full steam ahead on bringing stem cell-based therapeutics to market.
Leading Indicators
News
Insurance companies waste no time sponsoring prescription drug plans » PhRMA's on a quest to win patients over » India's new patent law grants 20-year monopolies » FDA faces pressure to develop guidances for testing generic biotech therapies.
Data
Public trust in FDA wanes post-Vioxx » PharmD's more popular than ever » Outsourcing soars.
Thought Leaders
Dr. Jerry Avorn, Harvard medical professor, thinks science—not marketing—should drive pharma.
Washington Report
A new approach to drug safety is needed at FDA. The agency says it can handle the problem internally—but critics are skeptical.
Jill Wechsler
Global Report
Novartis' recent acquisition of a German generics manufacturer could mean a shift in power for the top spot in generic drug making.
Sarah Houlton
Leadership
Status quo definitions of productivity no longer cut it. Leaders today are charged with fostering offices that stimulate creative thought, and inspire innovation.
Sander A. Flaum
Flaum Partners
Direct to Consumer
Last year, Pfizer got warned about not including risk information in its reminder ads for Viagra. Are these ads worth the risk for pharma companies—and consumers?
Amy Tobbagi
Contributing Writer
Marketing to Professionals
Industry is being called on to increase clinical trial trasparency. But pharm need not neglect the challenges posed by full disclosure.
Willow Duttge
Contributing Writer
Alternative Media
Integrating e-mail marketing with other channels can increase overall productivity for all marketing efforts. But beware of SPAM.
Paul Buta and Tina Jacobs
Optas
Meetings
Consolidated data for meeting planning helps pharma companies cut costs and ensure adherence to regulatory requirements.
Cindy D'Aoust
Martiz McGettigan
From the Editor
If pharma has to play by the rules when it comes to advertising, shouldn't everyone?
Patrick Clinton
Editor-in-Chief
Back Page
Pharma prides itself on innovation. But is first-in-class drug development always best for patients?
David Bloomberg
Accenture
People Update
Calendar of Events
Advertisers Index
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.